医学
脂肪性肝炎
非酒精性脂肪肝
内科学
肝硬化
脂肪肝
安慰剂
不利影响
胃肠病学
疾病
病理
替代医学
作者
Erenie Guirguis,John A. Dougherty,Krisy‐Ann Thornby,Yasmin Grace,Keri Mack
标识
DOI:10.1177/10600280241259528
摘要
Resmetirom serves as an attractive option in patients diagnosed with NASH with evidence of advanced fibrosis (F2-F3) in combination with exercise, diet, and other multimodal therapies targeting metabolic risk factors.
科研通智能强力驱动
Strongly Powered by AbleSci AI